9th Annual Cell Line Development & Engineering Asia & 10th Annual Biomanufacturing Agenda

Day 1: 3 November 2020

13:00
Chairperson’s Opening Remarks

Chen Guang, Consultant, Agency for Science, Technology and Research (A*STAR), Singapore


Joint Opening Plenary


13:10
Keynote Address:
China’s Big Leap towards BioPharma 2030  Innovation, Industrialization, Internationalization

Dr. Song Ru Lin, Executive President, China Pharmaceutical Innovation and Research Development Association (PhIRDA), China

13:30
Venture Capitals’ Roundtable:  
Show Me the Drug

  • Investment landscape in the Chinese biopharma market
  • Evaluating drug pipelines and development prospects
  • Mergers, expansion and JVs – Where do we see transactions picking up?
  • Financing new plants, new therapeutics, product launch and scaling-up operations – How do we review?
  • Manufacturing 4.0 – How do VCs and banks play a part in modernising the value chain?

Moderator:
Judith Li, Partner, Lilly Asia Ventures, China

Panelists:
Rani Jarkas, Chairman, Cedrus Group, Hong Kong
Lynn Yang, Managing Director, Sequoia Capital, China
Michael Xue, Managing Director, Morningside Ventures, China

14:15
Industry Spotlight:
Addressing Complex Protein Challenges with Lonza’s GS Xceed® Toolbox

Dr. Allison Porter, Head of Expression System Sciences, Lonza Pharma & Biotech, U.K.

14:45
Online Networking & Stretch Break


End of Joint Opening Plenary and 9th Annual Cell Line Development & Engineering Asia & 10th Annual Biomanufacturing commences

Innovative Bioprocess Development


15:00
Powder Handling and Hydration in Upstream Processes  

  • Evaluation of powder transfer bag designs for solid media and buffer handling
  • Trusted Weight Bags and streamlining incoming sampling requirements
  • Novel method for eliminating vortex mixing of powders
  • Supply chain security and supplier performance for a single use supplier

Scott Patterson, Vice President, Pharma / Biopharma, Technical Support, ILC Dover, Singapore

15:30
CMC development of Antibody Drug Conjugates

  • ADC introduction + ADC CMC challenge and approach

Dr. Huang Peng, Project Leader, ADC, TOT BIOPHARM, China

16:00
End of Conference Day 1

Day 2: 4 November 2020


Novel Advances In CLD Techniques & Technology


13:00
Chairperson’s Opening Remarks

Eric Chang, Head, Cell Line Development, JHL Biotech, China

13:00
Next-Generation Cell Line Development with Accelerated Timeline and High Productivity

  • Cell line development strategy for accelerated Covid-19 program approval
  • Codon impact on productivity
  • Next-generation sequencing application in cell line development

Zheng Zhang, Director II, Cell Line Development, WuXi Biologics, China

13:30
Single Cell Confidence – Creating the Double Lock of Assurance

Mark Stockdale, Amalgamator of Business and Biology, Solentim, UK

14:00
Using Recombinant Insulin in DoE for Media Development

  • Case study
  • Insulin – CHO Mab
  • Insulin – HEK293 Influenza Virus

Chantale Julien, Global Product Manager, Novo Nordisk Pharmatech, Denmark

14:30
Online Networking & Stretch Break

15:00
Difficult-to-Express Proteins Benefitting From Human Cells as a Production System

Dr. Vicky Goralczyk, Director, Cell Line and Bioprocess Development, Glycotope, Germany  

15:30
Next-Generation Cell Line Development Platform for Advanced Bispecific Antibodies Expression

Dr. Séverine Fagète, Vice President, Cell Line Development Services, Selexis, SA, Switzerland

16:00
End of Conference Day 2

Day 3: 5 November 2020


Biomanufacturing 2030 – China’s Great Leap


13:00
Scaling Up the Commercial Production of mAb Therapeutics in China

  • China’s capacity outlook and how do we capitalize on the mAb therapeutics markets
  • Teruisi’s breakthrough of mAb’s tech transfer and large-scale production in China while in-line with international standards – challenges and key learnings
  • Manufacture showcase to improve cost and efficiency

Dr. Wu You Ling, Chief Executive Officer, Zhejiang Teruisi Pharmaceuticals, China

13:30
Build vs. Buy – Long-term View of Capacity, Supply-Demand Balance and Investment in China’s Manufacturing Facilities

  • Insights on biopharma market segments driving new growth and where is the supply and demand
  • Identifying new market for biomanufacturing – emerging locations and site selection strategy
  • Manufacturing capacity outlook – utilization rates, new investment and a medium-term position
  • Commercial phase market outlook for CDMOs in China

Fireside Chat:
Jeff Li, General Manager, Lonza Pharma Biotech and Nutrition, China
Kevin Yang, Vice President, CMC and Manufacturing, I-MAB Biopharma, China

14:00
Online Networking & Stretch Break


Future Facilities & Smart Biomanufacturing


14:30
Tools and Best Practices for Successful Technology Transfer

Mahalia Corrales, Senior Director, Process Development & Technology, JHL Biotech, Taiwan

15:00
Manufacturing Technology Showcases – Improving Cost and Efficiency

  • Next gen manufacturing facilities design and investment trends
  • Smart automation case studies to increase facility efficiency and cost optimization
  • Intelligent bioreactors – advantages and benefits

Frank Ye, Senior Vice President, Technical Operations, Transcenta, China

15:30
Biomanufacturing Process Validation and Quality Risk Management

  • New process concepts of CQAs, CPPs, and QbDs
  • Best practices on quality risk management in bioprocess development
  • Case study on Bio-Thera’s manufacturing process quality control on the newest Humira biosimilar

Bao Cai, Senior Director, Manufacturing, Bio-Thera Solutions, China

16:00
End of Conference Day 3